AU Patent

AU2024205010B2 — CSF1R inhibitors for use in treating cancer

Assigned to Deciphera Pharmaceuticals LLC · Expires 2025-10-30 · 1y expired

What this patent protects

CSF1R INHIBITORS FOR USE IN TREATING CANCER Described herein are CSF1R inhibitors for use in methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor- associated macrophages (TAMs) and treatment of associat…

USPTO Abstract

CSF1R INHIBITORS FOR USE IN TREATING CANCER Described herein are CSF1R inhibitors for use in methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor- associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial 5 giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT). CSF1R INHIBITORS FOR USE IN TREATING CANCER

Drugs covered by this patent

Patent Metadata

Patent number
AU2024205010B2
Jurisdiction
AU
Classification
—
Expires
2025-10-30
Drug substance claim
No
Drug product claim
No
Assignee
Deciphera Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.